James Jones - 01 Dec 2022 Form 4 Insider Report for CUMBERLAND PHARMACEUTICALS INC (CPIX)

Role
Director
Signature
James Jones by /s/ John Hamm as attorney-in-fact
Issuer symbol
CPIX
Transactions as of
01 Dec 2022
Net transactions value
+$1,487
Form type
4
Filing time
23 Dec 2022, 16:11:38 UTC
Previous filing
23 Dec 2022
Next filing
27 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPIX Common Stock Purchase $72.23 +31 +0.12% $2.33 25,657 01 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $71.61 +31 +0.12% $2.31 25,688 02 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $67.89 +31 +0.12% $2.19 25,719 05 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $67.89 +31 +0.12% $2.19 25,750 06 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $67.58 +31 +0.12% $2.18 25,781 07 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $67.89 +31 +0.12% $2.19 25,812 08 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $66.65 +31 +0.12% $2.15 25,843 09 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $66.34 +31 +0.12% $2.14 25,874 12 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $87.2 +40 +0.15% $2.18 25,914 13 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $88.4 +40 +0.15% $2.21 25,954 14 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $44.8 +20 +0.08% $2.24 25,974 15 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $88.8 +40 +0.15% $2.22 26,014 16 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $155 +70 +0.27% $2.21 26,084 19 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $280 +121 +0.46% $2.31 26,205 20 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $195 +88 +0.34% $2.22 26,293 21 Dec 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.